Core Insights - The Shanghai Municipal Medical Procurement Management Office has released a list of drug varieties for public bidding and procurement supervision for September 2025, highlighting products that exceed the "yellow line" threshold, did not pass fairness assessments, or are under close monitoring [1][10] Group 1: Drug Varieties - The list includes exclusive products such as Ma Ren Run Chang Soft Capsules, Yunnan Baiyao Aerosol, and Bu Xin Qi Oral Liquid [1] - New applications exceeding the "yellow line" include exclusive products from Beijing Tongrentang and Yunnan Baiyao Group [1] - Existing products on the "yellow line" list include exclusive items like Regaglinide Metformin Tablets (II) from Zhejiang Tailisen Pharmaceutical [1] Group 2: Regulatory Framework - Since September 2018, Shanghai has implemented a public bidding mechanism for drug procurement, utilizing a pricing inquiry model based on "information push, green line reference, yellow line reminder, and red line interception" [9] - Starting from June 2024, the list will also include products that did not pass fairness assessments and those under close monitoring [9] Group 3: Procurement Guidelines - The Shanghai Municipal Medical Procurement Management Office emphasizes that the published list serves as a reminder for medical institutions to price reasonably based on market supply and demand, ensuring clinical needs are met while avoiding unreasonable price adjustments [10]

4月16日，上海市医药集中招标采购事务管理所(上海医药（601607）采购中心)公布了2025年2月挂网公 开议价超"黄线"、未通过公允性评估、重点监控药品幅度靠前且有一定采购金额的品种，其中利肺片、 活血通脉胶囊等8种药品被重点监控。 自2024年6月开始，上海市医药集中招标采购事务管理所会定期发布药品挂网公开议价采购监管品种名 单，记者统计发现，此次"上榜"的利肺片、肌苷注射液等药品已经成为监控名单的"常客"，重庆天致药 业股份有限公司与三普药业有限公司两家企业生产的利肺片更成为历次重点监控的"全勤生"。 两款利肺片成监控"全勤生" 此次公布的药品挂网公开议价采购监管品种名单涉及2025年2月挂网公开议价超"黄线"、未通过公允性 评估、重点监控药品幅度靠前且有一定采购金额的品种。重点监控品种方面，共有9家企业生产的利肺 片、活血通脉胶囊等8种药品被列入，具体包括利肺片(生产企业涉及重庆天致药业股份有限公司、三普 药业有限公司)、活血通脉胶囊(生产企业涉及重庆天致药业股份有限公司、乐普恒久远药业有限公司)、 注射用二羟丙茶碱(吉林津升制药有限公司)、注射用糜蛋白酶(吉林省辉南长龙生化药业股份有限公 司)、枣 ...